| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/03/2013 | CN102174479B Oncolytic virus for targeted treatment of human tumors and application thereof |
| 04/03/2013 | CN102174097B Actinoporin and application thereof |
| 04/03/2013 | CN102127054B 3-(substituted dihydroisoindol-2-yl)-2,6-piperidinedione polymorph and pharmaceutical composite |
| 04/03/2013 | CN102107008B DNA damage repair inhibitors for treatment of cancer |
| 04/03/2013 | CN102106866B Pharmaceutical composition and preparation method thereof |
| 04/03/2013 | CN102086195B Dasatinib polymorphic substance as well as preparation method and medicinal composition thereof |
| 04/03/2013 | CN102086182B Petasites tatewakianus Kitam. extract as well as preparation method and application thereof |
| 04/03/2013 | CN102070658B Dimer salt of steroid alkaloid and preparation and application thereof |
| 04/03/2013 | CN102070615B Nitroxyl radical anti-tumor medicaments |
| 04/03/2013 | CN101974529B TGF-beta specific siRNA containing free triphosphoric acid group and application thereof |
| 04/03/2013 | CN101967135B 4-aryl coumarin compound and preparation method and application thereof |
| 04/03/2013 | CN101921225B Pirfenidone compound, preparation method and application thereof |
| 04/03/2013 | CN101874826B Granulose rabdosia rubescens compound preparation and preparation method thereof |
| 04/03/2013 | CN101863927B Palladium coordination compound for antitumor drugs |
| 04/03/2013 | CN101857594B Tetrahydropyridoindole compounds, and preparation method and application thereof |
| 04/03/2013 | CN101808648B Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma |
| 04/03/2013 | CN101802196B RNAi mediated knockdown of NuMA for cancer therapy |
| 04/03/2013 | CN101721401B Application of beta hydroxyisovaleryl shikonin in medicament production |
| 04/03/2013 | CN101684121B New crystal form of pemetrexed diacid and method for preparing same |
| 04/03/2013 | CN101570494B N-phenyl-dichloroacetamide and derivatives as well as preparation method and application thereof |
| 04/03/2013 | CN101514177B Method for extracting lutein from marigold particles |
| 04/03/2013 | CN101456880B Phosphamidon amphipathic phthalocyanine derivates, preparation method and application thereof in phototherapy medicament preparation |
| 04/03/2013 | CN101365473B Pharmaceutical composition for treating or preventing ovarian cancer |
| 04/03/2013 | CN101356195B Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
| 04/03/2013 | CN101316587B 取代的吡唑化合物 Substituted pyrazole compound |
| 04/03/2013 | CN101313063B Cancer-rejection antigen peptide derived from glypican-3 (GPC3) for use in HLA-A2-positive patient and pharmaceutical comprising the antigen |
| 04/03/2013 | CN101297692B Extraction of glycosides from Vaccinium dunalianum Wight var. dunalianum and use thereof in health products |
| 04/03/2013 | CN101243039B Compounds and their salts specific to the PPAR receptors and the EGF receptors and use thereof in the medical field |
| 04/03/2013 | CN101172104B Processes of making and using pharmaceutical formulations of antineoplastic agents |
| 04/03/2013 | CN101068805B Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase |
| 04/03/2013 | CN101027099B Diagnostic marker for cancer |
| 04/02/2013 | US8410272 Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
| 04/02/2013 | US8410264 Heterocyclic oxime compounds |
| 04/02/2013 | US8410175 Anticancer effect enhancer |
| 04/02/2013 | US8410174 Method for treating arthritis |
| 04/02/2013 | US8410131 Cancer treatment |
| 04/02/2013 | US8410061 Variants of hedgehog protein that contain N-terminal modifications are described that can block hedgehog function; thus allowing these variants to serve as functional antagonists. These peptides have a primary amino acid sequence |
| 04/02/2013 | US8410059 CXCR4 antagonist and use thereof |
| 04/02/2013 | US8409612 Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
| 04/02/2013 | US8409572 Monoclonal antibodies with enhanced ADCC function |
| 04/02/2013 | US8409566 Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
| 04/02/2013 | CA2728541C Crystalline forms of thiazolidinedione compound and its manufacturing method |
| 04/02/2013 | CA2588410C 2-methylene-19-nor-1.alpha.-hydroxy-17-ene-homopregnacalciferol and its uses |
| 04/02/2013 | CA2555792C Therapeutic administration of the scrambled anti-angiogenic peptide c16y |
| 04/02/2013 | CA2553895C Use of 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, for the preparation of medication useful for the treatment of illnesses linked to pathological choroidal angiogenesis |
| 04/02/2013 | CA2553883C Anti-cancer antibodies with reduced complement fixation |
| 04/02/2013 | CA2550843C Novel phenylalanine derivatives |
| 04/02/2013 | CA2532799C Human antibody molecules for il-13 |
| 04/02/2013 | CA2531759C Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors |
| 04/02/2013 | CA2513881C Immunomodulatory compositions |
| 04/02/2013 | CA2494105C Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 04/02/2013 | CA2472647C Mammal prolactin variants |
| 04/02/2013 | CA2470920C Liposomal delivery of vitamin e based compounds |
| 04/02/2013 | CA2420543C Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| 03/28/2013 | WO2013044219A1 Methods of treating cancers with therapeutic nanoparticles |
| 03/28/2013 | WO2013044169A1 Methods for determining combination therapy with il-2 for the treatment of cancer |
| 03/28/2013 | WO2013044164A1 Methods to treat and/or prevent relapse in notch1-driven malignancies |
| 03/28/2013 | WO2013043973A2 Cachexia treatment |
| 03/28/2013 | WO2013043967A1 Romidepsin and 5 - azacitidine for use in treating lymphoma |
| 03/28/2013 | WO2013043961A1 Compounds useful as inhibitors of choline kinase |
| 03/28/2013 | WO2013043960A1 Compounds useful as inhibitors of choline kinase |
| 03/28/2013 | WO2013043933A2 Cd27l antigen binding proteins |
| 03/28/2013 | WO2013043826A1 Tricyclic compounds useful as protein kinase inhibitors |
| 03/28/2013 | WO2013043812A1 Logical enzyme triggered (let) layer-by-layer nanocapsules for drug delivery system |
| 03/28/2013 | WO2013043647A1 Cancer immunotherapy |
| 03/28/2013 | WO2013043569A1 Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| 03/28/2013 | WO2013043255A1 Methods and compositions for the treatment of ovarian cancer |
| 03/28/2013 | WO2013043192A1 Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders |
| 03/28/2013 | WO2013043128A1 Sall4 and uses thereof |
| 03/28/2013 | WO2013043002A1 Imide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same |
| 03/28/2013 | WO2013043001A1 Phenylimide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same |
| 03/28/2013 | WO2013042834A1 Radionuclide marked and drug carrying polymer hydrogel and a production method therefor, and pharmaceutical composition for treating cancer comprising same as an active ingredient |
| 03/28/2013 | WO2013042124A1 Use of strigolactones and strigolactone analogs for treating proliferative conditions |
| 03/28/2013 | WO2013042122A1 Beta-lactam compounds for enhancing t cell -mediated immune responses |
| 03/28/2013 | WO2013042006A1 Pyrrolopyrimidine and purine derivatives |
| 03/28/2013 | WO2013041895A1 Novel medicinal compounds |
| 03/28/2013 | WO2013041652A1 Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
| 03/28/2013 | WO2013041634A1 Substituted imidazopyridazines |
| 03/28/2013 | WO2013041606A1 Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| 03/28/2013 | WO2013041480A1 New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments |
| 03/28/2013 | WO2013041468A1 Benzoic acid derivatives as eif4e inhibitors |
| 03/28/2013 | WO2013041457A1 N-piperidin-4-yl derivatives |
| 03/28/2013 | WO2013041238A1 Use of kibra peptides, hdac inhibitor or proteasome inhibitor for improving anxiety disorders |
| 03/28/2013 | WO2013041204A1 Novel isocyanate and isothiocyanate compounds for cancer treatment |
| 03/28/2013 | WO2013041182A1 Crystallization of idarubicin hydrochloride |
| 03/28/2013 | WO2013041042A1 Pyrazole carboxamides as janus kinase inhibitors |
| 03/28/2013 | WO2013041038A1 Pyridine compounds as inhibitors of kinase |
| 03/28/2013 | WO2013041029A1 Novel soluble ctla4 variants |
| 03/28/2013 | WO2013041014A1 Platinum compound having amino- or alkylamino-containing succinic acid derivatives as leaving group, preparation method therefor, and use thereof |
| 03/28/2013 | WO2013040863A1 Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors |
| 03/28/2013 | WO2013040801A1 Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof |
| 03/28/2013 | WO2013040669A1 Compounds of the family of pterocarpan quinones, method for producing same, pharmaceutical composition, uses thereof and therapeutic method |
| 03/28/2013 | WO2013016720A3 Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases |
| 03/28/2013 | WO2013016580A3 Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer |
| 03/28/2013 | WO2012177684A9 Use of caspase 3 activity and its inhibitors |
| 03/28/2013 | WO2012173521A3 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon |
| 03/28/2013 | WO2012169822A3 Fusion protein for suppressing cancer cell growth and suppressing vasculogenesis, and anticancer composition comprising same |
| 03/28/2013 | WO2012169785A3 Symmetrically structured quinazoline derivatives |
| 03/28/2013 | WO2012165854A3 Long interfering dsrna simultaneously inducing an immune reaction and the inhibition of the expression of target genes |
| 03/28/2013 | WO2012162513A3 Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors |